ArticleAnnals of translational medicine2022
Article in Annals of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 38 citations in OpenAlex.
- Activation of the NF-ĸB Signaling Pathway by Lactobacillus plantarum and Lactobacillus casei Through Modulation of TLR4 and DC-SIGN Genes in an Oral Squamous Cell Carcinoma Rat Model.Cancer reports (Hoboken, N.J.) · 2026Article
- The Role of Next-Generation Probiotics in Colorectal Cancer Pathways: Mechanisms and Therapeutic Potential.Probiotics and antimicrobial proteins · 2026Review
- Identification and validation of butyrate metabolism-related biomarkers for colorectal cancer diagnosis.PeerJ · 2026Article
- FermentedInternational journal of medical sciences · 2026Article
- Implications of gut microbiota-mediated epigenetic modifications in intestinal diseases.Gut microbes · 2025Review
- Decoding the impact of gut microbiota on heart failure.Genes & diseases · 2025Review
- Molecular Mechanisms of Probiotic Action Against Gastrointestinal Cancers.International journal of molecular sciences · 2025Review
- The Encapsulation Strategies for Targeted Delivery of Probiotics in Preventing and Treating Colorectal Cancer: A Review.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- The combination ofmSystems · 2025Article
- Probiotics and human health: biological activities, nutritional aspects, immunomodulatory properties, applications, and future perspectives - a comprehensive review.Frontiers in immunology · 2025Review
- The power of microbes: the key role of gut microbiota in the initiation and progression of colorectal cancer.Frontiers in oncology · 2025Review
- Impact of Dietary Feeding Levels of Juvenile Red-Tail Catfish (Aquaculture nutrition · 2025Article
- Anticancer Effects ofLife (Basel, Switzerland) · 2024Article
- Immunomodulation aspects of gut microbiome-related interventional strategies in colorectal cancer.Medical oncology (Northwood, London, England) · 2024Review
- The Potential of Clostridium butyricum to Preserve Gut Health, and to Mitigate Non-AIDS Comorbidities in People Living with HIV.Probiotics and antimicrobial proteins · 2024Review
- Probiotics: Shaping the gut immunological responses.World journal of gastroenterology · 2024Article
- Clostridium butyricum, a future star in sepsis treatment.Frontiers in cellular and infection microbiology · 2024Review
- Clostridium butyricum inhibits epithelial-mesenchymal transition of intestinal carcinogenesis through downregulating METTL3.Cancer science · 2023Article
- Review
- Modulation of gut microbiota: a novel approach to enhancing the effects of immune checkpoint inhibitors.Therapeutic advances in medical oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methods: We established azoxymethane (AOM)/dextran sulfate sodium salt (DSS) model mice (male, 6-week-old C57BL/6J) and divided them into the control (Ctrl) and CB groups at the end of the second DSS cycle. Mice in the CB group received treatment with CB [1×10 Results: Mice in the CB group showed a lower incidence and total volume of CRC, more apoptotic cells in the tumor tissue, a lower level of IL-6, and a higher level of IL-10 compared with those in the Ctrl group. CB altered the composition of the gut microbiota and was enriched in the small intestine and tumor tissue. Moreover, CB restrained the proliferation and the expression of Conclusions: CB restrained the progression of CRC, improved the inflammation of AOM/DSS mice, altered the composition of their gut microbiota, and regulated the expression of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.